Review Article

Role of Exosomes in Chronic Liver Disease Development and Their Potential Clinical Applications

Chen Wang1,2, Jinwen Liu2, Yongmin Yan2, and Youwen Tan1

1The Third Hospital of Zhenjiang Affiliated Jiangsu University, Jiangsu University, Zhenjiang, 212005 Jiangsu, China
2School of Medicine, Jiangsu University, Zhenjiang, 212013 Jiangsu, China

Correspondence should be addressed to Youwen Tan; tanyw915@163.com

Received 28 February 2022; Revised 2 April 2022; Accepted 18 April 2022; Published 6 May 2022

Copyright © 2022 Chen Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Extracellular vesicles (EVs) are vesicular bodies (40-1000 nm) with double-layer membrane structures released by different cell types into extracellular environments, including apoptosis bodies, microvesicles, and exosomes. Exosomes (30-100 nm) are vesicles enclosed by extracellular membrane and contain effective molecules of secretory cells. They are derived from intracellular multivesicular bodies (MVBs) that fuse with the plasma membrane and release their intracellular vesicles by exocytosis. Research has shown that almost all human cells could secrete exosomes, which have a certain relationship with corresponding diseases. In chronic liver diseases, exosomes release a variety of bioactive components into extracellular spaces, mediating intercellular signal transduction and materials transport. Moreover, exosomes play a role in the diagnosis, treatment, and prognosis of various chronic liver diseases as potential biomarkers and therapeutic targets. Previous studies have found that mesenchymal stem cell-derived exosomes (MSC-ex) could alleviate acute and chronic liver injury and have the advantages of high biocompatibility and low immunogenicity. In this paper, we briefly summarize the role of exosomes in the pathogenesis of different chronic liver diseases and the latest research progresses of MSC-ex as the clinical therapeutic targets.

1. Introduction

Liver, as an essential metabolic organ of the body, plays an important physiological role in metabolizing toxic substances, storing liver sugar, and synthesizing secretory proteins. Chronic liver disease has become a serious public health problem with 2 million deaths worldwide per year. Minimally invasive liver biopsy remains the preferred method for pathological examination of liver disease [1], but its reliability depends on high sampling accuracy, and it is urgent to establish more reliable and noninvasive diagnostic methods to satisfy clinical demand.

The study of exosomes in liver diseases is a rapidly developing field. As the investigation develops in-depth, people have realized the critical role of exosomes in regulating cellular signal transduction and material transportation and focused on studying exosome-mediated chronic liver diseases. Exosomes from different cell types have different compositions (such as RNAs, proteins, and lipids) and thus have complex biological functions. The hepatocytes [2], Kupffer cells [3], hepatic stellate cells [4], and hepatic sinusoidal endothelial cells [5] that constitute the liver could all secrete or serve as target cells of exosomes, and the changes of the number and composition of these vesicles reflect the physiological and pathological state of liver. The quality and quantity of these exosomes vary from different liver states [6]. During the occurrence and development of liver diseases, exosomes can also be used as novel molecular biomarkers for monitoring the therapeutic effect of diseases.

Mesenchymal stem cells (MSCs) are kind of cells with the potential of self-renewal and multidifferentiation, which can be obtained from various human tissues. Exosomes derived from MSCs (MSC-ex) are tiny vesicles that carry and maintain the proteins and mRNA activity of secretory cells. As a natural cell-derived nanocarrier, MSC-ex have been reported to cross the blood-brain barrier [7]. They can directly enter the target cells to play biological roles, with higher biosafety and more stable signal transduction efficiency over parental MSCs. Therefore, MSC-ex have attracted widespread attention in the field of tissue regeneration and repair.
Liver fibrosis is a chronic liver disease characterized by the progressive accumulation of extracellular matrix components, leading to the development of cirrhosis. The formation of liver fibrosis is closely related to the progression of various liver diseases. During the formation of liver fibrosis, exosomes produced by various cells interact with each other to jointly regulate the changes of cytokines and cell populations and function as the fibrosis regulators in the occurrence and development of liver fibrosis, and the specific mechanism of their functions still needs to be further studied (Figure 1).

2.2. ALD and NAFLD

2.2.1. Alcoholic Liver Disease. Alcoholic liver disease (ALD) is a liver pathology associated with chronic alcohol consumption [19]. During ALD, the release of circulating exosomes increased, including specific proteome, miRNA, and lipid, which may be associated with cellular stress responses. By comparing EV components in plasma of healthy controls and patients with severe alcoholism, alcoholic cirrhosis, and alcoholic hepatitis, it was found that EV levels increased in patients with ALD and correlated with disease severity [20]. High EV levels predict poor prognosis in ALD patients. Regular consumption of alcohol causes inflammatory stimulation by inhibiting fatty acid oxidation, upregulating adipogenic genes, and changing lipid transportation.

Alcohol activates cellular regulatory networks that control inflammation and cell death, including the caspase path, which leads to the activation of apoptotic pathways and increases exosomes’ production [21]. Alcohol-mediated release of exosomes is rich in CYP2E1 [22] from hepatocytes. CYP2E1 is a member of the cytochrome P450 family, promoting monocyte polarization that secretes exosomes with high expression of CD40L and miR-122 [24]. Monocytes increased their sensitivity to lipopolysaccharides [25] after receiving exosomes rich in miR-122, and macrophages were activated and released many proinflammatory factors like IL-6, IL-17, and IL-1β after receiving CD40L [26]. During the progression of ALD, the toll-like receptor 4 (TLR4) pathway is activated and induces toll-receptor ligands binding to miR-155, triggering inflammation and liver injury. Hepatocyte-derived and monocyte-derived exosomes both regulate macrophage phenotypes, leading to the inflammatory phenotype of ALD. In alcoholic steatohepatitis, exosomes released by intestinal epithelial cells in the enterohepatic circulation had an adverse effect on hepatocyte activity and lipid accumulation [27], driving infiltration of macrophages and neutrophils [19]. In summary, these bioactive molecules released by exosomes mediate intercellular signal transduction and suggest the progression of ALD to alcoholic fatty liver (Figure 2). In addition, exosomes are widely present in body fluids and carry alcohol-related specific
components, which can also be used as markers for the diagnosis of alcoholic liver injury, but their specificity and sensitivity need to be evaluated.

2.2.2. Nonalcoholic Fatty Liver Disease. Nonalcoholic fatty liver disease (NAFLD) starts with steatosis and progresses to nonalcoholic steatohepatitis (NASH), which is one of the most common chronic liver diseases associated with obesity, insulin resistance, and genetic susceptibility [28] and has the risk of developing into terminal liver diseases [29]. Studies have shown that 20% of NAFLD patients could advance to NASH and eventually cirrhosis [30]. Exosomes play an essential role in the pathogenesis of NAFLD. NAFLD is characterized by hepatocyte dysfunction induced by lipid and macrophage-associated inflammation [31]. During the development of NAFLD, lipid toxicity signals promote monocytes to the liver and polarize into inflammatory macrophages [32]; the lipid-induced death receptor five signaling pathway is activated, and the damaged or stressed hepatocytes release exosomes that are closely related to the degree of liver injury [33]. Diet-related steatohepatitis affects exosome release and some obesity-related exosomes, such as miR-27A-3p, miR-27b-3p, miR-192, and miR-122 [34], overexpressed in circulating exosomes isolated from high-fat-fed mice. miR-199a-5p in circulating exosomes of high-fat-fed mice inhibits macrophage stimulation and fatty acid metabolism, thus promoting lipid accumulation in the liver [35]. In addition, lipids cause the accumulation of immature bone marrow cells, which release proinflammatory cytokines and induce apoptosis of natural killer T (NKT) cells. NKT apoptosis promotes the excessive production of TH-1 cytokines, leading to chronic inflammation. Lipotoxic exosomes further induce angiogenesis through vascular noninflammatory protein-1 and mediate its internalization by endothelial cells. Lipotoxic hepatocytes also produce exosomes rich in miR-17-92 clusters, absorbed by HSCs, leading to fibrotic activation [36].

The progression of NAFLD to NASH depends on the exosome-mediated cell-to-cell communications. After the passage of NAFLD into NASH, exosomes of hepatocytes rich in mtDNA are released. The mtDNA-rich exosomes activate TLR9 in KCs by triggering the secretion of proinflammatory cytokines, such as IL-1β and TNF-α, and aggravate the progression of NAFLD [37]. Interestingly, exosomes from adipose stem cells reduce adipose inflammation and lipid deposition by polarizing M2 macrophages and white

Figure 1: Functions of exosomes in the pathogenesis of liver fibrosis. Hepatocyte-derived exosomes activated by the exposure to alcohol, lipotoxic damage, and hepatitis virus. A variety of different pathways mediate chronic inflammation that exacerbate liver fibrosis. Immune cells secrete a large number of proinflammatory factors to promote the infiltration of inflammatory cells and aggravate liver inflammation. During liver injury, exosomes secreted by hepatocytes contain different types of RNAs, protein, and drive activation and function in hepatic stellate cells and macrophages. Meanwhile, LSEC vascularization and extracellular matrix deposition increased, resulting in fibrosis and liver dysfunction. The most significant markers of fibrosis are intrahepatic connective tissue dysplasia and massive diffuse extracellular matrix deposition. It is marked by upregulated expression of collagen, laminin, and α-SMA.
adipose tissue. Adipose tissue is an essential source of circulating miRNA, and adipose cells with Dicer specifically knocking out significantly reduce the numbers of circulating miRNA [38]. In addition, HepG2-derived exosomes can be actively internalized by adipocytes, thus stimulating transcriptome changes in adipocytes, specifically inducing inflammatory phenotypes in adipocytes [39]. These findings suggest that the secretion of vesicles containing unique substances may trigger the progression of NAFLD to other liver diseases by inducing the activation of macrophages and the release of inflammatory factors (Figure 3).

In summary, during the occurrence and development of alcoholic and nonalcoholic liver diseases, exosomes regulate the signal transduction and materials transfer between hepatocytes and inflammatory cells, affecting the activities of the liver mononuclear macrophage system and regulating the inflammatory responses.

2.3. Viral Hepatitis. There are about 1.5 million people worldwide die of hepatitis virus-related liver diseases every year [40], creating a serious public health problem. Persistent viral replication and low immunologic function result in severe liver parenchymal damage and increase the risk of viral hepatitis progression to terminal liver disease. Here we mainly introduce the application of exosomes in viral hepatitis B and C.

Exosomes are potent vectors for transmitting the hepatitis virus and transmitting nucleic acids and proteins of the virus from infected cells to uninfected cells. Exosomes secreted by hepatocytes infected with hepatitis C virus carry virus-derived Ago2 protein, HSP90, and miR-122 [41], mediating stable transmission of hepatitis virus in the liver [42]. On the one hand, exosome-mediated viral transportations help the virus evade surveillance by the immune system. miRNAs released from virus-infected hepatocytes inhibit the proliferation and survival of natural killer (NK) cells and escape the host’s innate immunity [43]. Exosomes containing HCV RNA reduce toll-like receptor 3 (TLR3) activation and interfere with antiviral ISG activation [44]. The expression of TIM-3/GAL-9 in exosomes secreted by HCV-infected hepatocytes increased, affecting the differentiation of monocytes and suppressing the body’s immune responses [45]. The complex microenvironments in the liver, on the other hand, could also identify particles carrying viral antigens, inducing the immune responses of target cells to the virus [46]. Innate immune responses to the virus removal depend on NK cells, dendritic cells (DCs), and T cells. Exosomes released from immune cells secrete the antiviral factors and immunosuppressive factors. NK cells also secrete exosomes with the natural killing ability and antiviral proteins, such as CD56 and perforin. DC is the most effective antigen-presenting cell against hepatitis virus attacks.
Macrophage-derived exosomes transfer antiviral responses induced by interferon-α (IFN-α) could be transmitted from liver nonsubstantial cells [47] and macrophages [48] to HBV-infected hepatocytes via exosomes to exert the function of antivirus. In addition, exosomes released by hepatocytes infected with HBV also carry HSP70 protein [49] and stimulate macrophages to express the NK cell-active receptor ligands through the signal transduction pathway, thus promoting the antiviral ability of NK cells. In some nonparenchymal cells in the liver, although hepatitis virus does not replicate in these cells, they still induce intracellular expression of cytokines like interferon I and III types that stimulate the immune system and exert an antiviral response. Release exosomes into virus-infected hepatocytes [47]. Interestingly, blocking the release of EVs severely inhibits viral replication but without suppressing the viability of host cells [50]. These studies have proved that exosomes play an essential role in virus transmission and immune regulation.

The regulation of exosome-mediated intercellular communications might be an effective method to control hepatitis virus transmission. Evidence has shown that exosomes released by hepatocytes during viral hepatitis are involved in the HSC-mediated liver fibrosis pathway. HCV-infected hepatocytes release exosomes enriched in miR-192 and miR-214 and deliver them to HSCs, resulting in HSC activation and transformation into myofibroblasts that highly express fibrotic components such as CNN2 [51]. HCV-infected hepatocytes could also release exosomes expressing miR-19a, which directly regulate the CSS-STAT3 axis and upregulate extracellular matrix (ECM) factors in HSC [52] and activate the profibrosis pathway of HSC through exosome-mediated autocrine [53]. In summary, the role of exosomes in viral hepatitis is complex, and the inhibition of the EV release may play an antiviral effect to a certain extent. Further animal experiments and preclinical studies for the function of exosomes will help to predict the prognosis of the diseases and develop new therapeutic strategies (Figure 4).

2.4. Hepatocellular Carcinoma. Hepatocellular carcinoma (HCC) is a common malignancy with a poor global survival rate. The main risk factors of HCC encompass viral hepatitis infection, excessive alcohol consumption, and smoking [54], but it is complicated and difficult to screen the pathogenesis of HCC.

Plentiful evidences suggest that exosomes derived from hepatoma carcinoma cells carry tumor-specific markers, which mediate the intercellular communication between cancer cell populations, and promote the migration and invasion of recipient cells. It was found that the expression of circ-0004277 in exosomes from hepatoma carcinoma cells upregulated and improved the expression of circ-0004277 in normal hepatocytes adjacent to hepatoma carcinoma cells through cell communications thus inducing epithelial-mesenchymal transformation (EMT) and promoting intrahepatic metastasis of HCC [55]. EMT is the key process of...
tumor metastasis [56], and tumor cells receiving EMT can release exosomes conducive to tumor metastasis [57]. High-throughput sequencing revealed that miR-374A-5p has the most significant differential expression among miRNA components in exosomes [57]. Recent studies also show that hepatoma carcinoma cells cultured with cancer-derived exosomes increase the number of cancer stem cells. Hepatoma carcinoma cells secrete exosomes that highly express Shh and activate the hedgehog pathway to promote tumorigenesis [58]. These results suggest that hepatoma carcinoma cells mediate the secretion of different exosomes, regulate the liver microenvironments through various pathways, and promote tumor migration and invasion.

In addition, the recurrence and metastasis of hepatocellular carcinoma can seriously affect the therapeutic effect of the disease. It is well known that hypoxia plays a key role in the progression of HCC [59]. Hypoxia increases the production of exosomes by HCC cells [60]. In a study of hypoxia-induced exosome expression, scholars found that exosomes released by HCC cells secrete exosomes that highly express Shh and activate the hedgehog pathway to promote tumorigenesis [58]. These results suggest that hepatoma carcinoma cells mediate the secretion of different exosomes, regulate the liver microenvironments through various pathways, and promote tumor migration and invasion.

In addition, the recurrence and metastasis of hepatocellular carcinoma can seriously affect the therapeutic effect of the disease. It is well known that hypoxia plays a key role in the progression of HCC [59]. Hypoxia increases the production of exosomes by HCC cells [60]. In a study of hypoxia-induced exosome expression, scholars found that exosomes released by HCC cells secrete exosomes that highly express Shh and activate the hedgehog pathway to promote tumorigenesis [58]. These results suggest that hepatoma carcinoma cells mediate the secretion of different exosomes, regulate the liver microenvironments through various pathways, and promote tumor migration and invasion.

3. Exosomes as Biomarkers for Liver Diseases

Early detection of liver diseases is one of the essential prerequisites for blocking the disease progression. Invasive liver biopsy remains the reference standard for diagnosing liver diseases, and novel, reliable, and noninvasive diagnostic methods are urgently needed. Exosomes from a variety of human tissues such as urine and blood are currently considered as source of noninvasive molecular biomarkers for early detection and prognosis of various liver diseases. The components of exosomes such as particular proteins and nucleic

![Figure 4: The schematic represents exosomes in viral hepatitis and their molecular mechanisms by which exosomes regulate cellular communication in liver. As indicated in the figure, the hepatitis B virus (HBV) and hepatitis C virus (HCV) rely on exosomes to spread viral RNAs and protein to adjacent liver cells, and these particles facilitate the spread of the virus as well as destroy the innate immune response of the host.](image-url)
acids can cross the blood-brain barrier, representing the physiological and pathological states of the liver.

Exosomes play a key role in mediating cell to cell communication and package delivery, and they can be used as diagnostic biomarkers. It was found that dozens of miRNAs significantly increased in the serum of HCC patients compared with healthy controls. Among them, miR-210 mediated by exosomes derived from hepatoma carcinoma cells increased and could be used as a biological marker for diagnosing HCC [65]. miR-638 in serum exosomes affects the occurrence of HCC by inhibiting the proliferation of cancer cells and is considered a tumor-specific miRNA marker. In patients with chronic hepatitis B, viral load is proportional to serum miR-122 level, and miR-146a level has an opposite trend, both involved in inflammatory and immune responses [66]. Low levels of serum miR-122 may indicate severe liver fibrosis. And the elevation of miR-21 suggests HBV-associated cirrhosis or HCC [67]. miR-19a and miR-155 levels are associated with advanced liver fibrosis in the serum exosomes of HCV patients, and the CD81 protein content in serum exosome was positively associated with inflammatory activity and severity of liver fibrosis [68].

Sphingolipids in plasma-derived EVs could be used as biomarkers in patients with alcoholic fatty liver disease. The impurities from lipoprotein have little interference, showing a high diagnostic value [69]. For example, miR-309, miR-30a, and miR-192 increased significantly in alcohol-induced liver injury, which has a high diagnostic value for the identification [20]. In patients with NAFLD, lipotoxic hepatocytes release exosomes highly expressing MLK3, and multiple miRNAs in serum of patients, such as miR-34a, miR-122, and miR-192, could be used as biomarkers of NAFLD [70] (Table 1).

Liver disease is a worldwide difficult problem. As part of liquid biopsy, exosomes are expected to be used in the early diagnosis of chronic liver disease. As a new generation of nanomedical diagnosis, people expect to build a nanodiagnostic platform based on EVs. Although further studies are needed to improve the specificity of exosome in various chronic liver diseases, we believe that exosomes as novel biomarkers have widespread clinical application value. It is necessary to combine multiple indicators as specific markers for early diagnosis and monitoring liver diseases to pursue unsatisfied clinical needs.

Figure 5: The detailed mechanism of exosomes in hepatocellular carcinoma (HCC). Hepatoma carcinoma cells influence neighboring cells through exosomes and established tumorigenic microenvironment. On one hand, cancer cell-derived exosomes promote diffusion of tumor contents to normal cells, promote epithelial-mesenchymal transformation and tumor angiogenesis, and promote stellate cell activation that is related to liver fibrosis pathway. On the other hand, cancer cell-derived exosomes could present and deliver relevant information to activate the immune responses of the body or inhibit immune cell function to promote tumor immune-escape.
Table 1: Exosomes as possible biomarkers of different liver diseases.

| Disease    | Source     | Content                                      | Expression | Clinical significance                                                                 | Refs.                        |
|------------|------------|----------------------------------------------|------------|--------------------------------------------------------------------------------------|------------------------------|
| Liver fibrosis | Serum      | miR-21, miR-122, miR-155, miR-214           | Up         | Detection, progression, and diagnosis of fibrogenesis                                | [20, 71–73]                 |
|            |            | miR-122                                       |            | Severe liver fibrosis; suggest NASH-induced liver fibrosis                          | [74]                        |
|            |            | miR-199a                                      | Down       | Significantly decreased in patients with cirrhosis and HCC                        | [75]                        |
| ALD        | Serum/plasma| miR-122, miR-155, miR-146, miR-192, miR-30a, miR-340, miR-744 | Up         | Differential diagnosis and progression of ALD                                      | [76, 77, 20]                |
| NAFLD      | Serum      | miR-21, miR-34a, miR-192                     | Up         | Potential diagnostic biomarker and forecast progression                            | [70, 78, 79]                |
|            | Hepatocytes| miR-122,                                     | Up         | An attractive therapeutic/the target of lipid metabolism                           | [80]                        |
| Viral hepatitis | Serum    | miR-19a                                       | Up         | A potential novel biomarker for diagnosis                                           | [82, 83]                    |
|            |            | miR-483-5p, miR-672-5p                        | Up         | Progression of liver fibrosis in CHC                                               | [84]                        |
|            | Serum      | miR-122, Ago2, HSP90                         | Up         | Enhance HCV replication                                                            | [41]                        |
|            | Macrophage | miR-29                                        | Up         | HCV infection (in vitro)                                                          | [85]                        |
|            | Serum      | miR-106b, miR-1274a, miR-130a, miR-140-3p, miR-151, miR-3p, miR-181a, miR-21, miR-24, miR-375, miR-93 | Down       | Progression of liver fibrosis in CHC                                               | [84]                        |
|            | Plasma     | miR-150, -192, -200b, -92a                   | Down       | Decreased in HBV or HCV patients                                                   | [86]                        |
| HCC        | Serum      | LINC00161                                     | Up         | Predict tumor growth and metastasis in HCC                                         | [87]                        |
|            |            | miR-21, miR-92b, miR-93, miR-665, miR-155     | Up         | Detection, prognosis, and recurrence of HCC                                        | [88–92]                    |
|            |            | miR-1247-5p, miR-224, miR-210-3p              | Up         | Detection, diagnosis, and therapeutic target                                       | [93, 94] [65]              |
|            |            | miR-638                                        | Up         | Specific and promising for surveillance marker                                      | [95]                        |
|            | Serum      | miR-744, miR-9-3p, miR-125b, miR-718          | Down       | Detection, prognosis, recurrence, and therapeutic target of HCC                   | [96–99]                    |
|            | Plasma     | miR-92a-3p                                    | Up         | Potential diagnostic biomarker of HCC                                              | [103]                       |

Up: upregulated; down: downregulated; HCC: hepatocellular carcinoma; ALD: alcoholic liver disease; NAFLD: nonalcoholic fatty liver disease.
4. MSC-ex Exert Applications in the Treatments of Liver Diseases

Liver transplantation (LT) remains the standard treatment for almost all the end-stage liver diseases (ESLDs), but the imbalance between donors and the patients and the complex postoperative complications are the major challenges. There are few specific targeted drugs for liver diseases clinically at present, and it is urgent to develop new drugs for ESLD.

Mesenchymal stem cells (MSCs) are pluripotent stem cells that derived from mesoderm and widely distributed in almost all the body tissues. Study has found that the proteins and miRNAs contained in mesenchymal stem cells (MSCs) play their functions in the pathological process of liver and regulate liver microenvironment. Exosomes are small vesicles secreted by cells. Compared with mesenchymal stem cells (MSCs), the exosomes secreted by MSCs are smaller and lower immunogenicity. They are easier to produce and store and even easier to avoid formation of ectopic tissue or tumor masses and avoid some of the regulatory issues that allogeneic mesenchymal stem cells face. Therefore, the transplantation of MSC-ex has become the focus of injury repair and regenerative medicine. Studies have found that exosomes could pass through the intercellular spaces and deliver “therapeutic molecules” between different cells in chronic liver diseases. In tumor microenvironment, MSC-ex could transmit extracellular signals and inhibit tumor angiogenesis by downregulation of vascular endothelial growth factor (VEGF) [104]. hucMSC-ex could transfer bioactive components and reduce carbon tetrachloride- (CCl4-) induced mouse liver fibrosis [105], inhibiting EMT and collagen production and upregulating the expression of apoptotic protein Bcl-2 in hepatocytes. Correspondingly, exosomes from amnion-derived MSCs (Ad-MSCs) attenuate CCl4-induced liver injury by inhibiting stellate cells and Kupffer cell activation [106]. Exosomes from human-induced pluripotent stem cells (iPSCs) promote regeneration against the ischemia/reperfusion model in mice [107]. Moreover, exosomes derived from BM-MSCs could suppress the Wnt/β-catenin pathway axis to improve liver fibrosis [108]. In addition, exosomes from healthy people may benefit patients with liver fibrosis. For example, exosomes from normal hepatocytes reduce the expression of fibrosis-related genes in mice induced by CCl4. Exosomes derived from human hepatocytes indicate an excellent ability of antifibrosis and anti-inflammatory in the NASH model of mice, inhibiting HCC growth and stimulating its apoptosis by the delivery of miR-451 and miR-31 [109]. These studies provide a theoretical basis for the potential therapeutic effects of exosomes in liver diseases (Table 2).

Recent research has suggested that exosomes contain organ-specific targeting molecules specific to recipient tissues to some extent, and gene modification can improve the therapeutic effect of MSC exosomes. In addition to the direct therapeutic effects of exosomes on chronic liver diseases, exosomes can also be used as vectors to deliver specific biomolecules to target cells for biological functions, with the development of nanotechnology and its deepening in the interdisciplinary fields like biomedicine. Nanovesicles, traditionally used as a single drug carrier, have been endowed with a variety of new functions, while their activity in the body has been improved. Cell-derived exosomes are a kind of endogenous nanodrug treatment system based on cell derivatives. Compared with traditional synthetic nanocarriers prepared in chemical environment, they have excellent biocompatibility and bioavailability. How to give full play to the advantages of nanomaterials and at the same time to synthesize or extract innovative nanodrugs with low toxicity as diagnosis tracer or treatment of diseases has become the frontier of the development of nanomaterials. Naturally occurring exosomes have the disadvantages of short half-life and fast clearance rate. Recent studies have shown that modified exosomes or hydrogel-coated exosomes can prolong the retention rate in vivo and improve the therapeutic effect. In addition, it has been suggested that the efficacy of MSC-ex may depend on its biological composition and, more importantly, on the responsiveness of the recipient to MSC-ex [110]. Some substances in the environment of MSC-ex may also be important components that inhibit its activity. In the treatment of peri-implantitis in dental implant treatments with MSC-ex, scholars have found the phenomenon of oxidative stress and vessel morphology alterations under the exposure of titanium (Ti) particle, which influence the function of MSC-ex [111].

In addition, quantitative criteria for exosome as a treatment means should be established, and various clinical trials are needed to determine its safety, efficacy, and feasibility in the body. With the progress of science and technology, the methods of exosome extraction are changing rapidly; however, there is no unified extraction scheme for exosomes to date.

5. Conclusion and Prospect

This review summarizes the role of MSC-ex in alleviating the progression of chronic liver diseases and the value of exosomes as potential diagnostic and therapeutic markers in chronic liver diseases. Exosomes are closely connected with chronic liver diseases, and the change of their composition may reflect the underlying disease progression. The release of exosomes increased in various chronic liver diseases, and these small vesicles could carry molecules with biological activity such as proteins, nucleic acids, and lipids for relatively stable transmission between cells and participate in a variety of pathophysiological processes, such as cytokine secretion, macrophage activation, extracellular matrix remodeling, and hepatic stellate cell activation. The characteristics of exosomes carrying small molecules and the biological activity determine their potential role in the treatment of liver diseases. Many studies have been carried out in chronic liver diseases and have made some progress. However, exosomes are as fraught with expectations as they are with problems. Most of the current studies on exosomes for the treatment of chronic liver diseases are based on cell experiments and animal experiments, and the clinical phase of the investigation remains to be explored. Moreover, for EVs in circulating body fluid or blood, exosomes and microvesicles are defined by size, but they cannot be
Table 2: Therapeutic effects of MSC-derived exosomes in liver diseases.

| Source          | Active ingredients | Models                                      | Function                                                                                      | Refs     |
|-----------------|--------------------|---------------------------------------------|------------------------------------------------------------------------------------------------|----------|
| HiPSC-MSCs      | —                  | Ischemia-reperfusion/liver injury           | Protects the liver from ischemia-reperfusion injury                                        | [112]    |
| Ad-MSCs         | miRNA-181-5p       | CCl4/mouse liver injury                    | Activates autophagy to prevent liver fibrosis                                               | [113]    |
|                 | miR-122            | HepG2 mice transplanted with tumor          | Enhance chemotherapeutic sensitivity of liver cancer                                        | [114]    |
|                 | miR-122            | CCl4/mouse liver fibrosis                  | Inhibits collagen synthesis and stellate cell proliferation                                | [115]    |
|                 | miR-17             | GalN/TNF-α induced mouse ALF models        | Targeting TXNIP and reducing inflammasome activation of NLRP3 in macrophages              | [116]    |
| HUC-MSCs        | —                  | CCl4/mouse liver fibrosis                  | Inhibits hepatocyte EMT and collagen production                                             | [105]    |
|                 | GPX1               | CCl4/liver failure                          | Inhibits oxidative stress of hepatocytes                                                   | [117]    |
|                 | miR-451a           | EMT of hepatocellular carcinoma cells       | Inhibits ADAM10 and suppresses the paclitaxel resistance, cell cycle transition, proliferation, migration, and invasion | [118]    |
|                 | miR-455-3p         | IL-6/acute liver injury                    | Attenuates macrophage infiltration and reduces inflammatory factors in serum                | [119]    |
|                 | —                  | ALF                                         | Inhibits NLRP3 activation in macrophage and decreases proinflammatory cytokine level        | [120]    |
| PL-MSCs         | —                  | ALF                                         | The upregulated CRP participates in vascular remodeling and promotes liver regeneration    | [121]    |
| ESC-MSCs        | —                  | CCl4/acute liver injury                    | Promotes liver cell proliferation                                                          | [122]    |
|                 | IL-6               | Con-a/mouse liver injury                   | Inhibits HSC activation                                                                   | [108]    |
| BM-MSCs         | miR-92b-3p, miR-23b-3p, miR-204-3p, miR-1247-3p, miR-326-5p | CCl4/acute liver injury | Macrophages transfer antifibrotic miR-223-enriched exosomes into hepatocytes | [123]    |
|                 | miR-125b           | CCl4/rat liver fibrosis                    | Upregulates TNF-stimulated gene 6 and/or represses mitochondrial oxidative phosphorylation  | [124]    |
| CP-MSCs         | —                  | CCl4/acute liver injury                    | Promotes liver regeneration and inhibits HSC activation                                    | [125]    |

HiPSC-MSCs: MSCs derived from human-induced pluripotent stem cells; Ad-MSCs: adipose-derived MSCs; HUC-MSCs: human umbilical cord MSCs; PL-MSCs: placenta-derived MSCs; ESC-MSCs: embryonic stem cell-derived MSCs; BM-MSCs: bone marrow-derived MSCs; CP-MSCs: chorionic plate-derived MSCs.
distinguished by size. Therefore, it becomes especially important to distinguish circulating EVs by expression of specific biomarkers in exosomes and microvesicles. We also need to further explore the precise molecular mechanisms of exosome biogenesis, release, and interaction with target cells in chronic liver diseases for clinical transformation and define the criteria for biological properties of exosomes during mass production. With the participation of a growing number of scholars, it is believed that exosomes will be widely used in clinical practice in the near future, bringing good news to patients.

**Abbreviations**

ADSC: Adipose-derived stem cell
Ad-MSC: Adipose-derived MSC
ALD: Alcoholic liver disease
ALF: Acute liver failure
BM-MSC: Bone marrow-derived MSC
CC4: Carbon tetrachloride
CRC: Colorectal cancer
CRP: C-reactive protein
CTGF: Connective tissue growth factor
cDC: Dendritic cell
ECM: Extracellular matrix
EMT: Epithelial-mesenchymal transformation
ESC-MSC: Embryonic stem cell-derived MSC
ESLD: End-stage liver disease
EV: Extracellular vesicle
HBV: Hepatitis B virus
HCC: Hepatocellular carcinoma
HSC: Hepatic stellate cell
IFN-α: Interferon-α
IPSC: Induced pluripotent stem cell
LC: Liver cirrhosis
LT: Liver transplantation
miR: MicroRNA
MSC-ex: Mesenchymal stem cell-derived exosomes
MVB: Multivesicular body
NAFLD: Nonalcoholic fatty liver disease
NASH: Nonalcoholic steatohepatitis
NK: Natural killer T
PL-MSC: Placenta-derived MSC
TLR: Toll-like receptor
TNF-α: Tumor necrosis factor α
VEGF: Vascular endothelial growth factor.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Chen Wang and Jinwen Liu drafted the manuscript, and Yongmin Yan and Youwen Tan gave the final approval of the submitted manuscript. All authors read and approved the manuscript and agreed to be accountable for all aspects of the research to ensure its accuracy and integrity. Chen Wang and Jinwen Liu contributed equally to this work.

**Acknowledgments**

This work was supported by the Jiangsu Graduate Scientific Research and Innovation Program (No. KYCX20_3091), the National Natural Science Foundation of China (Grant number 81670549), the Jiangsu Provincial Critical Research and Development Program (Grant numbers BE2020775 and BE2021690), the Zhenjiang Key Research and Development Program (Grant number SH2020002), the Six Talent Peaks Project of Jiangsu Province, and the Backbone Teacher of the Blue Project in Jiangsu Province.

**References**

[1] H. P. Kim, M. O. Idowu, A. R. Mospan et al., "Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis," *Alimentary Pharmacology & Therapeutics*, vol. 54, no. 11-12, pp. 1472–1480, 2021.

[2] H. Nojima, C. M. Freeman, R. M. Schuster et al., "Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate," *Journal of Hepatology*, vol. 64, no. 1, pp. 60–68, 2016.

[3] Y. Jiao, P. Xu, H. Shi, D. Chen, and H. Shi, "Advances on liver cell-derived exosomes in liver diseases," *Journal of Cellular and Molecular Medicine*, vol. 25, no. 1, pp. 15–26, 2021.

[4] J. Gao, B. Wei, T. M. de Assuncao et al., "Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis," *Journal of Hepatology*, vol. 73, no. 5, pp. 1144–1154, 2020.

[5] Q. Ye, Y. Zhou, C. Zhao, L. Xu, and J. Ping, "Salidroside inhibits CCl4-induced liver fibrosis in mice by reducing activation and migration of HSC induced by liver sinusoidal endothelial cell-derived exosomal SphK1," *Frontiers in Pharmacology*, vol. 12, article 677810, 2021.

[6] D. Povero, A. Eguchi, H. Li et al., "Circulating extracellular vesicles with specific proteome and liver miRNAs are potential biomarkers for liver injury in experimental fatty liver disease," *PloS One*, vol. 9, no. 12, article e113651, 2014.

[7] S. Dabrowska, A. Andrezewska, B. Lukomska, and M. Janowski, "Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles," *Journal of Neuroinflammation*, vol. 16, no. 1, p. 178, 2019.

[8] B. Codispoti, M. Marrelli, F. Paduano, and M. Tatullo, "Nanometric bio-banked MSC-derived exosome (nanobiome) as a novel approach to regenerative medicine," *Journal of Clinical Medicine*, vol. 7, no. 10, p. 357, 2018.

[9] M. Tatullo, B. Marrelli, M. J. Zullo et al., "Exosomes from human periapical cyst-MSCs: theranostic application in Parkinson's disease," *International Journal of Medical Sciences*, vol. 17, no. 5, pp. 657–663, 2020.

[10] Z. Jiao, Y. Ma, Y. Wang et al., "Protective effect of adipose-derived mesenchymal stem cell secretome against hepatocyte apoptosis induced by liver ischemia-reperfusion with partial heptatectomy injury," *Stem Cells International*, vol. 2021, Article ID 9969372, 12 pages, 2021.

[11] Q. Shi, D. Wang, X. Ding, X. Yang, and Y. Zhang, "Exosome-shuttled miR-7162-3p from human umbilical cord derived mesenchymal stem cells repair endometrial stromal cell injury by restricting APOL6," *Archives of Biochemistry and Biophysics*, vol. 707, article ??, 2021.
[12] W. C. Zhou, Q. B. Zhang, and L. Qiao, "Pathogenesis of liver cirrhosis," World Journal of Gastroenterology, vol. 20, no. 23, pp. 7312–7324, 2014.
[13] T. Higashi, S. L. Friedman, and Y. Hoshida, "Hepatic stellate cells as key target in liver fibrosis," Advanced Drug Delivery Reviews, vol. 121, p. 27, 2017.
[14] C. Y. Zhang, W. G. Yuan, P. He, J. H. Lei, and C. X. Wang, "Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets," World Journal of Gastroenterology, vol. 22, no. 48, pp. 10512–10522, 2016.
[15] A. Charrier, R. Chen, L. Chen et al., "Exosomes mediate intercellular transfer of pro-fibrogenic connective tissue growth factor (CCN2) between hepatic stellate cells, the principal fibrotic cells in the liver," Surgery, vol. 156, no. 3, pp. 548–555, 2014.
[16] R. Wang, Q. Ding, U. Yaqoob et al., "Exosome adherence and internalization by hepatic stellate cells triggers sphingosine-1-phosphate-dependent migration," The Journal of Biological Chemistry, vol. 290, no. 52, pp. 30684–30696, 2015.
[17] L. Chen, R. Chen, S. Kemper, M. Cong, H. You, and D. R. Brigstock, "Therapeutic effects of serum extracellular vesicles in liver fibrosis," Journal of Extracellular Vesicles, vol. 7, no. 1, article 1461505, 2018.
[18] S. Tanwar, F. Rhodes, A. Srivastava, P. M. Trembaling, and W. M. Rosengren, "Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C," World Journal of Gastroenterology, vol. 26, no. 2, pp. 109–123, 2020.
[19] K. L. Seitz, R. Bataller, H. Cortez-Pinto et al., "Alcoholic liver disease," Nature Reviews. Disease Primers, vol. 4, no. 1, p. 16, 2018.
[20] F. Momen-Heravi, B. Saha, K. Kodys, D. Catalano, A. Satishchandran, and G. Szabo, "Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis," Journal of Translational Medicine, vol. 13, no. 1, p. 261, 2015.
[21] G. Szabo and F. Momen-Heravi, "Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets," Nature Reviews. Gastroenterology & Hepatology, vol. 14, no. 8, pp. 455–466, 2017.
[22] S. Kumin, N. Sinha, K. A. Gerth, M. A. Rahman, M. M. Yalnapur, and N. M. Midde, "Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications," Biochemical and Biophysical Research Communications, vol. 491, no. 3, pp. 675–680, 2017.
[23] B. Saha, J. C. Bruneau, K. Kodys, and G. Szabo, "Alcohol-induced miR-27a regulates differentiation and M2 macrophage polarization of normal human monocytes," Journal of Immunology, vol. 194, no. 7, pp. 3079–3087, 2015.
[24] V. K. Verma, H. Li, R. Wang et al., "Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles," Journal of Hepatology, vol. 64, no. 3, pp. 651–660, 2016.
[25] F. Momen-Heravi, S. Bala, K. Kodys, and G. Szabo, "Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS," Scientific Reports, vol. 5, no. 1, p. 9991, 2015.
[26] A. Eguchi, R. Yan, S. Q. Pan et al., "Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice," Journal of Molecular Medicine (Berlin, Germany), vol. 98, no. 7, pp. 1021–1034, 2020.
[27] A. Lamas-Paz, L. Morán, J. Peng et al., "Intestinal epithelial cell-derived extracellular vesicles modulate hepatic injury via the gut-liver Axis during acute alcohol injury," Frontiers in Pharmacology, vol. 11, article 603771, 2020.
[28] R. F. Schwabe, I. Tabas, and U. B. Pajvani, "Mechanisms of fibrosis development in nonalcoholic steatohepatitis," Gastroenterology, vol. 158, no. 7, pp. 1913–1928, 2020.
[29] M. P. Johnston, J. Patel, and C. D. Byrne, "Causes of mortality in non-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD)," Current Pharmaceutical Design, vol. 26, no. 10, pp. 1079–1092, 2020.
[30] E. Cobbina and F. Akhlaghi, "Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transportors," Drug Metabolism Reviews, vol. 49, no. 2, pp. 197–211, 2017.
[31] Y. He, R. M. Rodrigues, X. Wang et al., "Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis," The Journal of Clinical Investigation, vol. 131, no. 3, 2021.
[32] S. H. Ibrahim, P. Hirsova, and G. J. Gores, "Non-alcoholic steatohepatitis pathogenesis: sublethal hepatic injury as a driver of liver inflammation," Gut, vol. 67, no. 5, pp. 963–972, 2018.
[33] P. Hirsova, S. H. Ibrahim, A. Krishnan et al., "Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes," Gastroenterology, vol. 150, no. 4, pp. 956–967, 2016.
[34] C. Castaño, S. Kalko, A. Novials, and M. Párrizas, "Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 48, pp. 12158–12163, 2018.
[35] Y. Li, Y. Luan, J. Li et al., "Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism," Hepatology International, vol. 14, no. 6, pp. 1057–1074, 2020.
[36] L. A. Ban, N. A. Shackel, and S. V. McLennan, "Extracellular vesicles: a new frontier in biomarker discovery for nonalcoholic fatty liver disease," International Journal of Molecular Sciences, vol. 17, no. 3, p. 376, 2016.
[37] I. Garcia-Martinez, N. Santoro, Y. Chen et al., "Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9," The Journal of Clinical Investigation, vol. 126, no. 3, pp. 859–864, 2016.
[38] T. Thomou, M. A. Mori, J. M. Dreyfuss et al., "Adipose-derived circulating miRNAs regulate gene expression in other tissues," Nature, vol. 542, no. 7642, pp. 450–455, 2017.
[39] S. Wang, M. Xu, X. Li et al., "Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties," Journal of Hematology & Oncology, vol. 542, no. 7642, pp. 450–455, 2017.
[40] M. Matić, A. Lombardi, M. U. Mondelli, and M. Colombo, "Elimination of hepatitis C in Europe: can WHO targets be achieved?," Clinical Microbiology and Infection, vol. 26, no. 7, pp. 818–823, 2020.
[41] T. N. Bukong, F. Momen-Heravi, K. Kodys, S. Bala, and G. Szabo, "Exosomes from hepatitis C infected patients...
transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90,” *PLoS Pathogens*, vol. 10, no. 10, article e1004424, 2014.

[42] Z. Liu, X. Zhang, Q. Yu, and J. J. He, “Exosome-associated hepatitis C virus in cell cultures and patient plasma,” *Biochemical and Biophysical Research Communications*, vol. 455, no. 3-4, pp. 218–222, 2014.

[43] Y. Yang, Q. Han, Z. Hou, C. Zhang, Z. Tian, and J. Zhang, “Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction,” *Cellular & Molecular Immunology*, vol. 14, no. 5, pp. 465–475, 2017.

[44] O. Grünvogel, O. Colasanti, J. Y. Lee et al., “Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cell-Mediated Intercellular Communication between Hepatic Stellate Cells,” *Journal of Virology*, vol. 92, no. 24, 2018.

[45] J. Li, K. Liu, Y. Liu et al., “Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity,” *Nature Immunology*, vol. 14, no. 8, pp. 793–803, 2013.

[46] Z. Yao, Y. Qiao, X. Li et al., “Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity,” *Journal of Virology*, vol. 92, no. 24, 2018.

[47] J. Radons and G. Multhoff, “Immunostimulatory functions of membrane-bound and exported heat shock protein 70,” *Exercise Immunology Review*, vol. 11, pp. 17–33, 2005.

[48] Y. Aydin, A. R. Koksal, V. Reddy et al., “Extracellular vesicle release promotes viral replication during persistent HCV infection,” *Cells*, vol. 10, no. 5, p. 984, 2021.

[49] J. H. Kim, C. H. Lee, and S. W. Lee, “Exosomal transmission of microRNA from HCV replicating cells stimulates differentiation in hepatic stellate cells,” *Molecular Therapy-Nucleic Acids*, vol. 14, pp. 483, 2019.

[50] P. B. Devhare, R. Sasaki, S. Shrivastava, A. M. Di Bisceglie, R. Ray, and R. B. Ray, “Correction for Devhare et al., “Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells,” *Journal of Virology*, vol. 91, no. 10, 2017.

[51] T. Chida, M. Ito, K. Nakashima et al., “Critical role of CREB1-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells,” *Hepatology*, vol. 66, no. 5, pp. 1430–1443, 2017.

[52] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA: a Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021.

[53] C. Zhu, Y. Su, L. Liu, S. Wang, Y. Liu, and J. Wu, “Circular RNA hsa_circ_0004277 stimulates malignant phenotype of hepatocellular carcinoma and epithelial-mesenchymal transition of peripheral cells,” *Front Cell Developmental Biology*, vol. 8, article 585565, 2020.

[54] Z. Qu, J. Feng, H. Pan, Y. Jiang, Y. Duan, and Z. Fa, “Exosomes derived from HCC cells with different invasion characteristics mediated EMT through TGF-β/Smad signaling pathway,” *Oncotargets and Therapy*, vol. Volume 12, pp. 6897–6905, 2019.

[55] Q. Lin, C. R. Zhou, M. J. Bai et al., “Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis,” *American Journal of Translational Research*, vol. 12, no. 3, pp. 1080–1095, 2020.

[56] L. Li, J. Zhao, Q. Zhang et al., “Cancer cell-derived exosomes promote HCC tumorigenesis through hedgehog pathway,” *Frontiers in Oncology*, vol. 11, article 756205, 2021.

[57] J. P. Joseph, M. K. Harishankar, A. A. Pillai, and A. Devi, “Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC,” *Oral Oncology*, vol. 80, p. 23, 2018.

[58] Y. Yu, Z. Min, Z. Zhou et al., “Hypoxia-induced exosomes promote hepatocellular carcinoma proliferation and metastasis via miR-1273f transfer,” *Experimental Cell Research*, vol. 385, no. 1, article 111649, 2019.

[59] H. Sun, Q. Meng, C. Shi et al., “Hypoxia-inducible exosomes facilitate liver-tropic premetastatic niche in colorectal cancer,” *Hepatology*, vol. 74, no. 5, pp. 2633–2651, 2021.

[60] N. Zheng, S. Zhang, W. Wu, N. Zhang, and J. Wang, “Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma,” *Pharmacological Research*, vol. 166, article 105507, 2021.

[61] M. Al-Geffari, N. A. Ahmad, A. H. Al-Shargawi, A. M. Youssef, D. Alnaqeb, and K. Al-Rubeaan, “Risk factors for thyroid dysfunction among type 2 diabetic patients in a highly diabetic mellitus prevalent society,” *International Journal of Endocrinology*, vol. 2013, Article ID 417920, 6 pages, 2013.

[62] W. Chen, L. Huang, J. Liang, Y. Ye, S. He, and J. Niu, “Hepatocellular carcinoma cells-derived exosomal microRNA-378b enhances hepatocellular carcinoma angiogenesis,” *Life Sciences*, vol. 273, article 119184, 2021.

[63] X. J. Lin, J. H. Fang, X. J. Yang et al., “Hepatocellular carcinoma cell-secreted exosomal microRNA-210 promotes angiogenesis in vitro and in vivo,” *Molecular Therapy-Nucleic Acids*, vol. 11, p. 243, 2018.

[64] M. H. van der Ree, L. Jansen, Z. Kruize et al., “Plasma MicroRNA levels are associated with hepatitis B e antigen status and treatment response in chronic hepatitis B patients,” *The Journal of Infectious Diseases*, vol. 215, no. 9, pp. 1421-1429, 2017.

[65] S. Bao, J. Zheng, N. Li et al., “Serum microRNA levels as a noninvasive diagnostic biomarker for the early diagnosis of hepatitis B virus-related liver fibrosis,” *Gut Liver*, vol. 11, no. 6, pp. 860–869, 2017.

[66] L. J. Niu, Y. M. Zhang, T. Huang, X. F. Sun, and S. X. Luo, “Exosomal microRNA-155 as a biomarker for hepatic fibrosis diagnosis and progression,” *Annals of Translational Medicine*, vol. 9, no. 2, p. 137, 2021.

[67] T. S. Sehrawat, J. P. Arab, M. Liu et al., “Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis,” *Hepatology*, vol. 73, no. 2, pp. 571–585, 2021.

[68] C. H. Liu, J. Ampuero, A. Gil-Gómez et al., “miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis,” *Journal of Hepatology*, vol. 69, no. 6, pp. 1335–1348, 2018.

[69] F. Royo, K. Schlangen, L. Palomo et al., “Transcriptome of extracellular vesicles released by hepatocytes,” *PLoS One*, vol. 8, no. 7, article e68693, 2013.
J. Zhang, D. Li, R. Zhang, P. Gao, R. Peng, and J. Li, “The miR-21 potential of serving as a biomarker for liver diseases in clinical practice,” *Biochemical Society Transactions*, vol. 48, no. 5, pp. 2295–2305, 2020.

L. Chen, A. Charrier, Y. Zhou et al., “Epigenetic regulation of connective tissue growth factor by microRNA-214 delivery in exosomes from mouse or human hepatic stellate cells,” *Hepatology*, vol. 59, no. 3, pp. 1118–1129, 2014.

T. Csak, S. Bala, D. Lippai et al., “miR-182 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohapatitis,” *Liver International*, vol. 35, no. 2, pp. 532–541, 2015.

K. S. Amr, W. M. Ezzat, Y. A. Elhosary, A. E. Hegazy, H. H. Fahim, and R. R. Kamel, “The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma,” *Gene*, vol. 575, no. 1, pp. 66–70, 2016.

S. Bala, J. Petrasek, S. Mundkur et al., “Circulating micro-RNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases,” *Hepatology*, vol. 56, no. 5, pp. 1946–1957, 2012.

A. Eguchi, R. G. Lazaro, J. Wang et al., “Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood,” *Hepatology*, vol. 65, no. 2, pp. 475–490, 2017.

C. Y. Lai, K. Y. Yeh, C. Y. Lin et al., “MicroRNA-21 plays multiple oncometabolic roles in the process of NAFLD-related hepatocellular carcinoma via PI3K/AKT, TGF-β, and STAT3 signaling,” *Cancers (Basel)*, vol. 13, no. 5, p. 940, 2021.

J. Ding, M. Li, X. Wan et al., “Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease,” *Scientific Reports*, vol. 5, no. 1, article 13729, 2015.

C. Esau, S. Davis, S. F. Murray et al., “miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting,” *Cell Metabolism*, vol. 3, no. 2, pp. 87–98, 2006.

J. X. Jiang and N. J. Török, “MLK3 as a regulator of disease progression in non-alcoholic steatohepatitis,” *Liver International*, vol. 34, no. 8, pp. 1131-1132, 2014.

R. T. Marquez, S. Bandyopadhyay, E. B. Wendlandt et al., “Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans,” *Laboratory Investigation*, vol. 90, no. 12, pp. 1727–1736, 2010.

P. B. Devhare, R. Sasaki, S. Shrivastava, A. M. Di Biscaglia, R. Ray, and R. B. Ray, “Exosome-mediated intercellular communication between hepatitis C virus-infected hepatocytes and hepatic stellate cells,” *Journal of Virology*, vol. 91, no. 6, 2017.

Y. Murakami, H. Toyoda, T. Tanahashi et al., “Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease,” *PLoS One*, vol. 7, no. 10, article e48366, 2012.

T. Kouwaki, Y. Fukushima, T. Daito et al., “Extracellular vesicles including exosomes regulate innate immune responses to hepatitis B virus infection,” *Frontiers in Immunology*, vol. 7, p. 335, 2016.

J. Lambrecht, P. Jan Poortmans, S. Verhulst, H. Reynaert, I. Mannaeerts, and L. A. van Grunsven, “Circulating ECV-associated miRNAs as potential clinical biomarkers in early stage HBV and HCV induced liver fibrosis,” *Frontiers in Pharmacology*, vol. 8, p. 56, 2017.

L. Sun, Y. Su, X. Liu et al., “Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma,” *Journal of Cancer*, vol. 9, no. 15, pp. 2631–2639, 2018.

H. Wang, L. Hou, A. Li, Y. Duan, H. Gao, and X. Song, “Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma,” *Biomed Res Int*, vol. 2014, article 864894, 5 pages, 2014.

T. Nakano, I. H. Chen, C. C. Wang et al., “Circulating exosomal miR-92b: its role for cancer immunoeediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence,” *American Journal of Transplantation*, vol. 19, no. 12, pp. 3250–3262, 2019.

X. Xue, X. Wang, Y. Zhao, R. Hu, and L. Qin, “Exosomal miR-93 promotes proliferation and invasion in hepatocellular carcinoma by directly inhibiting TIMP2/TP53INP1/CDKN1A,” *Biochemical and Biophysical Research Communications*, vol. 502, no. 4, pp. 515–521, 2018.

Z. Qu, J. Wu, J. Wu et al., “Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis,” *Oncotarget*, vol. 8, no. 46, pp. 80666–80678, 2017.

Y. Matsuura, H. Wada, H. Eguchi et al., “Exosomal miR-155 derived from hepatocellular carcinoma cells under hypoxia promotes angiogenesis in endothelial cells,” *Digestive Diseases and Sciences*, vol. 64, no. 3, pp. 792–802, 2019.

T. Fang, H. Lv, G. Lv et al., “Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer,” *Nature Communications*, vol. 9, no. 1, p. 191, 2018.

Y. Cui, H. F. Xu, M. Y. Liu et al., “Mechanism of exosomal microRNA-224 in development of hepatocellular carcinoma and its diagnostic and prognostic value,” *World Journal of Gastroenterology*, vol. 25, no. 15, pp. 1890–1899, 2019.

Y. Yokota, T. Noda, Y. Okumura et al., “Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells,” *Cancer Science*, vol. 112, no. 3, pp. 1275–1288, 2021.

J. Tang, Y. Li, K. Liu et al., “Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma,” *Minerva Medica*, vol. 109, no. 1, pp. 15–23, 2018.

G. Wang, W. Zhao, H. Wang et al., “Exosomal MiR-744 inhibits proliferation and sorafenib chemoresistance in hepatocellular carcinoma by targeting PAX2,” *Medical Science Monitor*, vol. 25, pp. 7209–7217, 2019.

W. Liu, J. Hu, K. Zhou et al., “Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma,” *Oncotargets and Therapy*, vol. 10, pp. 3843–3851, 2017.

K. Sugimachi, T. Matsumura, H. Hirata et al., “Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation,” *British Journal of Cancer*, vol. 112, no. 3, pp. 532–538, 2015.

M. Shi, Y. Jiang, L. Yang, S. Yan, Y. G. Wang, and X. J. Lu, “Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma,” *Journal of Cellular Biochemistry*, vol. 119, no. 6, pp. 4711–4716, 2018.
stem cell-derived microvesicles inhibit hepatoma growth in carcinoma patients,” *Oncology Letters*, vol. 16, no. 3, pp. 3267–3273, 2018.

[102] W. Sohn, J. Kim, S. H. Kang et al., “Serum exosomal micro-RNAs as novel biomarkers for hepatocellular carcinoma,” *Experimental & Molecular Medicine*, vol. 47, no. 9, p. e184, 2015.

[103] B. Yang, X. Feng, H. Liu et al., “High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma,” *Oncogene*, vol. 39, no. 42, pp. 6529–6543, 2020.

[104] X. Li, C. Li, L. Zhang et al., “The significance of exosomes in the development and treatment of hepatocellular carcinoma,” *Molecular Cancer*, vol. 19, no. 1, p. 1, 2020.

[105] T. Li, Y. Yan, B. Wang et al., “Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis,” *Stem Cells and Development*, vol. 22, no. 6, pp. 845–854, 2013.

[106] M. Ohara, S. Ohnishi, H. Hosono et al., “Extracellular vesicles from amnion-derived mesenchymal stem cells ameliorate hepatic inflammation and fibrosis in rats,” *Stem Cells International*, vol. 2018, Article ID 3212643, 15 pages, 2018.

[107] Y. Du, D. Li, C. Han et al., “Exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect liver against hepatic ischemia/reperfusion injury via activating sphingosine kinase and sphingosine-1-phosphate signaling pathway,” *Cellular Physiology and Biochemistry*, vol. 43, no. 2, pp. 611–625, 2017.

[108] X. Rong, J. Liu, X. Yao, T. Jiang, Y. Wang, and F. Xie, “Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway,” *Stem Cell Research & Therapy*, vol. 10, no. 1, p. 98, 2019.

[109] V. Fonsato, F. Collino, M. B. Herrera et al., “Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor microRNAs,” *Stem Cells*, vol. 30, no. 9, pp. 1985–1998, 2012.

[110] L. Kordelas, E. Schwich, R. Dittrich et al., “Individual immune-modulatory capabilities of MSC-derived extracellular vesicle (EV) preparations and recipient-dependent responsiveness,” *International Journal of Molecular Sciences*, vol. 20, no. 7, 2019.

[111] E. Bressan, L. Ferroni, C. Gardin et al., “Metal nanoparticles released from dental implant surfaces: potential contribution to chronic inflammation and peri-implant bone loss,” *Materials*, vol. 12, no. 12, p. 2036, 2019.

[112] X. Qi, K. T. Ng, Q. Lian et al., “Glutathione peroxidase 3 delivered by hiPSC-MSCs ameliorated hepatic IR injury via inhibition of hepatic senescence,” *Theranostics*, vol. 8, no. 1, pp. 212–222, 2018.

[113] Y. Qu, Q. Zhang, X. Cai et al., “Exosomes derived from miR-181-5p-modified adipose tissue-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation,” *Journal of Cellular and Molecular Medicine*, vol. 21, no. 10, pp. 2491–2502, 2017.

[114] G. Lou, X. Song, F. Yang et al., “Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma,” *Journal of Hematology & Oncology*, vol. 8, no. 1, p. 122, 2015.